Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB053914 in Advanced Malignancies
NCT02587598Phase 2Terminated
- Sponsor
- Incyte
- Start
- Dec 2015
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of INCB053914 in solid tumor, acute myeloid leukemia (AML), myelofibrosis (MF) and 3 more (9 arms), sponsored by Incyte. Primary endpoints: Number of Participants With Adverse Events at 7 months and Objective Remission Rate at 6 months. Started Dec 2015; status: terminated.
02
Drugs
INCB053914
03
Conditions
solid tumoracute myeloid leukemia (AML)myelofibrosis (MF)multiple myeloma (MM)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02587598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02587598.